Kelyniam Global (OTC: KLYG), a maker of custom cranial implants, today announced that it has completed the successful sale of restricted shares of Kelyniam’s common stock in a private placement to certain accredited investors effective with the closing of the offering period on November 30, 2024. No warrants were offered as part of this investment....Read More

Kelyniam Global (OTC: KLYG) a maker of custom cranial implants, today announced results for the third quarter ended September 30, 2024.  “Kelyniam has consistently delivered strong performance year on year,” said Ross Bjella, CEO ofKelyniam. “Our unwavering focus on overnight service and quality has been reflected in our third-quarter results.” Financial Highlights (Nine months ended...Read More

Kelyniam Global (OTC: KLYG), a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024. Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include: Total revenue of $957,447 compared to $ 596,455, an increase of 60.5% Gross Margin of $743,719 compared to...Read More

Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOP™ fixation system has received 510(k) clearance from the FDA for use with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant. The Cranial LOOP™ family of cranial fixation devices is a smart system made of PEEK-OPTIMA™, a biocompatible polymer,...Read More

Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2023. “The company set a quarterly unit sales record in the fourth quarter which contributed to achieving slight unit volume growth over 2022,” said Ross Bjella, Kelyniam’s CEO. “While Q4 sales were up 40% over the previous...Read More

Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its third quarter ended September 30, 2023. “Despite the weak sales performance in the past two quarters, we believe this is a temporary slowdown and remain optimistic about the future,” said Ross Bjella, Kelyniam’s CEO. “The company has not yet seen the...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its half year ended June 30, 2023. “Unit sales for the first half of 2023 were flat as compared to last year. Our financial results were adversely affected due to timing associated with way we recognize revenue.” said Ross...Read More

CANTON, Conn., May 18, 2023 — Kelyniam Global (OTC: KLYG), a leading maker of custom cranial implants, today announced results for its quarter ended March 31, 2023. “I’m pleased to announce that Kelyniam has expanded our licensing agreement with Bioplate to allow the Company to sell Osteopore products in select markets in the U.S. Kelyniam...Read More

Kelyniam Global (OTC: KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2022. The complete financials are available here. “2022 was the sixth year in a row that Kelyniam has meaningfully increased sales while successfully competing against much larger competitors” said Ross Bjella, Kelyniam’s CEO. “Neurosurgeons rely on...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended September 30, 2022. “Revenues in Q3 were significantly ahead of last year and we expect continued strong sales performance through the end of the year”, said Ross Bjella, Kelyniam’s Chairman and CEO. “The quarter over quarter...Read More